US2021198625A1PendingUtilityA1
Low oxygen culture conditions for maintaining retinal progenitor cell multipotency
Assignee: THE SCHEPENS EYE RES INSTITUTEPriority: Jun 14, 2011Filed: Dec 23, 2020Published: Jul 1, 2021
Est. expiryJun 14, 2031(~4.9 yrs left)· nominal 20-yr term from priority
C12N 5/062C12N 5/0623A61K 35/30C12N 2500/02A61P 27/02
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Claims
exact text as granted — not AI-modified1 - 19 . (canceled)
20 . A composition comprising an isolated, expanded substantially homogenous population of multipotent retinal progenitor cells and a stabilizer or a preservative, wherein the retinal progenitor cells express heterodimers of both HIF1 alpha with the aryl hydrocarbon receptor nuclear translocator (ARNT also known as HIF1β) and HIF2 alpha with the aryl hydrocarbon receptor nuclear translocator 2 (ARNT2 also known as HIF2β) and wherein the retinal progenitor cells are expanded in culture media at a level of from about 1% to about 6% oxygen concentration.Join the waitlist — get patent alerts
Track US2021198625A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.